Boston Scientific (BSX) is gaining traction in the international markets. New regulatory approvals and accretive acquisitions bode well for long-term growth. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold).Factors Driving BSX SharesBoston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In Europe, the Middle East and Africa (EMEA), Boston Scientific is success ...

Boston Scientific Corporation (BSX) has entered into a definitive agreement to acquire Intera Oncology Inc., a Boston-based life science company. The acquisition expands the company’s interventional oncology offerings with the Intera 3000 Hepatic Artery Infusion Pump and floxuridine — a chemotherapy drug — both of which are approved by the FDA.The transaction is expected to close in the first half of 2025, subject to closing conditions. Boston Scientific expects the deal to have an immaterial impact on adju ...

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastasesMARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy drug – both of which are approved by the U.S. Food and Drug Administration. Th ...

It has been about a month since the last earnings report for Boston Scientific (BSX) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Boston Scientific Q3 Earnings Beat E ...

Boston Scientific Corporation (BSX) recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device. The trial data provided clinical evidence indicating that LAAC with the WATCHMAN FLX device is safe and superior to oral anticoagulation (OAC) therapy for reducing the risk of long-term bleeding events in patients who have undergone an ablation. The OPTION trial data were presented at the American Heart Ass ...

Boston Scientific’s (BSX) growth in the third quarter of 2024 was backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Meanwhile, headwinds, such as currency movements and dull macroeconomic conditions, raise concern for Boston Scientific.In the past year, this Zacks Rank #3 (Hold) company’s shares have rallied 66.1% compared with the industry’s 21.4% growth and the S&P 500 comp ...

On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.The WATCHMAN implant device is about the size of a quarter and shaped like a parachute. It is implanted into the heart to close off the left atrial appendage, a blind pouch of heart tissue to prevent blood clots from forming and causing a stroke.Key findings from the study comparing the device to first-line oral anti ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablationMARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagu ...

Boston Scientific Corporation (NYSE:BSX) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-Anello - VP & GM of Interventional Cardiology Conference Call Participants Danielle Antalffy - UBS Danielle Antalffy So good morning, everyone. Thanks so much for joining us. And for those who don't know me, I'm Danielle Antalffy, I'm the U.S. Medtech analyst here at UBS. Very lucky to have with us Boston Scientif ...

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global market size for kidney stone management reached a value of USD 1.80 billion in 2023. The market is expected to grow at a CAGR of 5.20% between 2024-2032 and attain a value of USD 2.84 billion by 2032. Increasing prevalence of kidney stones, technological advancements in treatment options, and rising awareness about kidney health a ...